


Quest study provides diagnostic insights on the evolving drug crisis and reveals physicians' perspectives on the struggle to treat chronic pain

Drug Misuse in America 2019: Physician Perspectives and Diagnostic Insights on the Evolving Drug Crisis, a Quest Diagnostics Health Trends™ report, presents findings from analysis of more than 4.4 million deidentified aggregated clinical drug monitoring tests performed by Quest Diagnostics for patients from all 50 states and the District of Columbia from 2011 through 2018. The report also incorporates findings from a survey conducted by The Harris Poll, commissioned by Quest Diagnostics and Center on Addiction, of 500 primary care physicians in the United States.

More than half of patients misuse medications

Drug monitoring can provide clinicians with insights into multiple forms of possible misuse, including substance use disorders, dangerous drug combinations, and incomplete treatment or diversion.



Drug misuse is not confined to any single patient category, it spans gender and age group—of the 51% who showed signs of misuse:


Rates of misuse were virtually identical for males and females



Misuse rates were higher for men and women of reproductive age (15-45)



Misuse remains high across all age groups




*Based on drug monitoring tests performed on general population only

Reluctance to treat chronic pain

Many physicians are struggling to treat chronic pain, caught between a justified reluctance to prescribe opioids and a reasonable worry that the opioid epidemic will give way to misuse of other prescription or illicit drugs.

83% agree that because of the opioid crisis, it is considerably harder now to treat patients suffering from chronic pain

72% say though we may see a decrease in opioid-related deaths, the trade-off is a greater number of patients whose pain is not properly managed



62% fear we will be trading the opioid crisis for another prescription drug crisis

Physicians seek more education and see prescription drug monitoring as part of the solution

To combat prescription drug misuse, the healthcare community and policy makers have the opportunity to develop resources and tools to confront prescription drug misuse and protect patients from substance use disorders. A majority of physicians recognize a need for more education about addiction—from what to do if a patient shows signs of a substance use disorder, to how to taper patients off opioids.

At least 7 out of 10 physicians state they:



73% would like more information on when to refer patients to an addiction specialist

76% would like more information on how to monitor for prescription drug addiction

We can help you manage patients prescribed controlled substances and identify potential drug misuse

Quest Diagnostics offers proven drug monitoring tools to help you protect your patients' health.

Our state-of-the-art drug testing

- Comprehensive drug screening options to cover prescription, nonprescription, and illicit drugs
- Fast turnaround time and results confirmation
- Connectivity with over 650 EHR systems
- One lab that addresses all your testing needs

The Quest Diagnostics medMATCH® report

- Fast and easy-to-read report that interprets drug test results at a glance
- Quarterly reporting that provides practice level data and analytics

Toxicology expertise at your fingertips

- Our industry-leading toxicology experts are available to help you with test selection and results consultation
- **1.877.40.RXTOX** (1.877.407.9869)

QuestDrugMonitoring.com

- The latest Quest Diagnostics Health Trends™ report
- State-by-state overview of the latest misuse data
- Searchable drug monitoring test code directory
- Blog addressing some of the latest industry trends and news
- Clinician-patient communications training and support
- Resource center of training and educational materials

Learn more. Talk to your Quest Diagnostics Sales Representative or visit [QuestDrugMonitoring.com](https://www.questdiagnostics.com/questdrugmonitoring)